CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade BB Biotech AG - BION CFD

    41.20
    0.48%
    0.45
    Low: 40.5
    High: 41.25
    Market Trading Hours* (UTC) Open now
    Closes on Friday at 15:20

    Mon - Fri: 07:00 - 15:20

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.45
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.014983 %
    Charges from full value of position ($-2.85)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.014983%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.007239 %
    Charges from full value of position ($-1.38)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.007239%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency CHF
    Margin 5%
    Stock exchange Switzerland
    Commission on trade 0%

    *Information provided by Capital.com

    BB Biotech AG ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 41.45
    Open* 40.65
    1-Year Change* -17.55%
    Day's Range* 40.5 - 41.25
    52 wk Range 35.35-60.20
    Average Volume (10 days) 52.23K
    Average Volume (3 months) 1.35M
    Market Cap 2.38B
    P/E Ratio -100.00K
    Shares Outstanding 54.85M
    Revenue 765.00K
    EPS -6.39
    Dividend (Yield %) 6.63562
    Beta 1.18
    Next Earnings Date Jan 19, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 18, 2024 41.45 0.30 0.73% 41.15 41.55 40.65
    Apr 17, 2024 41.80 0.10 0.24% 41.70 42.20 41.20
    Apr 16, 2024 42.50 1.50 3.66% 41.00 42.70 41.00
    Apr 15, 2024 42.30 0.00 0.00% 42.30 42.70 41.70
    Apr 12, 2024 42.50 -0.40 -0.93% 42.90 43.20 42.20
    Apr 11, 2024 42.45 -0.30 -0.70% 42.75 43.10 42.15
    Apr 10, 2024 42.25 -1.00 -2.31% 43.25 43.25 42.10
    Apr 9, 2024 43.00 0.25 0.58% 42.75 43.20 41.90
    Apr 8, 2024 42.65 -0.10 -0.23% 42.75 42.95 42.60
    Apr 5, 2024 42.75 0.35 0.83% 42.40 43.05 42.40
    Apr 4, 2024 42.90 -0.70 -1.61% 43.60 43.65 42.65
    Apr 3, 2024 43.60 0.55 1.28% 43.05 43.90 42.95
    Apr 2, 2024 43.65 -1.10 -2.46% 44.75 45.20 42.90
    Mar 28, 2024 45.40 0.45 1.00% 44.95 45.55 44.50
    Mar 27, 2024 44.95 0.30 0.67% 44.65 45.15 44.60
    Mar 26, 2024 45.05 0.40 0.90% 44.65 45.25 44.60
    Mar 25, 2024 44.60 -0.35 -0.78% 44.95 46.05 44.10
    Mar 22, 2024 46.50 -1.05 -2.21% 47.55 47.55 46.50
    Mar 21, 2024 47.75 0.00 0.00% 47.75 48.05 47.20
    Mar 20, 2024 47.00 0.50 1.08% 46.50 47.60 46.40

    BB Biotech AG Events

    Time (UTC) Country Event
    Friday, April 26, 2024

    Time (UTC)

    05:00

    Country

    CH

    Event

    Q1 2024 BB Biotech AG Earnings Release
    Q1 2024 BB Biotech AG Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1.261 -343.591 741.784 728.166 5.777
    Revenue 1.261 -343.591 741.784 728.166 5.777
    Cost of Revenue, Total 1.726 0.986 0.883 1.243 1.086
    Gross Profit -0.465 -344.577 740.901 726.923 4.691
    Total Operating Expense 359.012 60.188 48.678 49.494 474.505
    Selling/General/Admin. Expenses, Total 38.747 52.595 41.755 42.375 41.849
    Interest Expense (Income) - Net Operating 314.265 0 427.09
    Other Operating Expenses, Total 4.274 6.607 6.04 5.876 4.48
    Operating Income -357.751 -403.779 693.106 678.672 -468.728
    Interest Income (Expense), Net Non-Operating 0 -0.962 -1.857 -1.173 -2.544
    Net Income Before Taxes -357.751 -404.741 691.249 677.499 -471.272
    Net Income After Taxes -357.812 -404.808 691.174 677.431 -471.343
    Net Income Before Extra. Items -357.812 -404.808 691.174 677.431 -471.343
    Net Income -357.812 -404.808 691.174 677.431 -471.343
    Income Available to Common Excl. Extra. Items -357.812 -404.808 691.174 677.431 -471.343
    Income Available to Common Incl. Extra. Items -357.812 -404.808 691.174 677.431 -471.343
    Diluted Net Income -357.812 -404.808 691.174 677.431 -471.343
    Diluted Weighted Average Shares 55.0113 55.3637 55.3912 55.4 55.4
    Diluted EPS Excluding Extraordinary Items -6.50433 -7.3118 12.4781 12.228 -8.508
    Dividends per Share - Common Stock Primary Issue 2.85 3.85 3.6 3.4 3.05
    Diluted Normalized EPS -6.50433 -7.3118 12.4781 12.228 -8.508
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total revenue 0.1 0.017 0.649 -0.001 220.988
    Revenue 0.1 0.017 0.649 -0.001 220.988
    Cost of Revenue, Total 1.669 1.442 1.108 0.777 0.358
    Gross Profit -1.569 -1.425 -0.459 -0.778 220.63
    Total Operating Expense 48.475 13.337 254.488 35.16 10.691
    Selling/General/Admin. Expenses, Total 6.981 7.352 8.943 9.478 9.369
    Other Operating Expenses, Total 0.69 1.437 1.223 0.776 0.964
    Operating Income -48.375 -13.32 -253.839 -35.161 210.297
    Interest Income (Expense), Net Non-Operating -0.144 0 0
    Net Income Before Taxes -48.375 -13.464 -253.839 -35.161 210.297
    Net Income After Taxes -48.39 -13.478 -253.855 -35.164 210.278
    Net Income Before Extra. Items -48.39 -13.478 -253.855 -35.164 210.278
    Net Income -48.39 -13.478 -253.855 -35.164 210.278
    Income Available to Common Excl. Extra. Items -48.39 -13.478 -253.855 -35.164 210.278
    Income Available to Common Incl. Extra. Items -48.39 -13.478 -253.855 -35.164 210.278
    Diluted Net Income -48.39 -13.478 -253.855 -35.164 210.278
    Diluted Weighted Average Shares 54.7503 56.1583 54.8283 54.8625 54.9029
    Diluted EPS Excluding Extraordinary Items -0.88383 -0.24 -4.63 -0.64095 3.83
    Dividends per Share - Common Stock Primary Issue 0 0 0 2.85 0
    Diluted Normalized EPS -0.88383 -0.24 -4.63 -0.64095 3.83
    Interest Expense (Income) - Net Operating 39.135 3.106 243.214 24.129 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 3053.39 3644.08 3963.14 3554.57 3086.84
    Cash and Short Term Investments 3053.3 2943.95 3261.48 2854.38 2386.25
    Cash & Equivalents 1.948 2.835 6.816 30.707 22.072
    Short Term Investments 3051.35 2941.11 3254.66 2823.67 2364.18
    Total Receivables, Net 0 1.521 0 0.334
    Accounts Receivable - Trade, Net 0 1.521 0 0.334
    Other Current Assets, Total 0.092 700.135 700.139 700.19 700.263
    Total Assets 3053.39 3644.08 3963.14 3554.57 3086.84
    Total Current Liabilities 367.254 360.589 75.588 161.594 202.332
    Accounts Payable 0 6.576 6.359 13.139
    Notes Payable/Short Term Debt 363 355 63 150 0
    Current Port. of LT Debt/Capital Leases 185
    Other Current Liabilities, Total 4.254 5.589 6.012 5.235 4.193
    Total Liabilities 367.254 360.589 75.588 161.594 202.332
    Total Long Term Debt 0 0 0 0 0
    Total Equity 2686.14 3283.49 3887.55 3392.97 2884.51
    Common Stock 11.08 11.08 11.08 11.08 11.08
    Retained Earnings (Accumulated Deficit) 2711.56 3281.62 3884.71 3381.89 2873.43
    Treasury Stock - Common -36.508 -9.205 -8.241
    Total Liabilities & Shareholders’ Equity 3053.39 3644.08 3963.14 3554.57 3086.84
    Total Common Shares Outstanding 54.846 55.2926 55.2853 55.4 55.4
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 2520.74 2578.46 2595.33 3053.39 3028.18
    Cash and Short Term Investments 2520.64 2573.63 2595.12 3053.3 3028.07
    Cash & Equivalents 0.322 0.9 0.759 1.948 3.025
    Short Term Investments 2520.31 2572.73 2594.36 3051.35 3025.05
    Total Receivables, Net 4.602
    Accounts Receivable - Trade, Net 4.602
    Other Current Assets, Total 0.104 0.232 0.214 0.092 0.108
    Total Assets 2520.74 2578.46 2595.33 3053.39 3028.18
    Total Current Liabilities 306.64 315.97 319.364 367.254 306.88
    Accounts Payable 1.494 4.478
    Notes Payable/Short Term Debt 302.1 308.5 315.5 363 303
    Other Current Liabilities, Total 3.046 2.992 3.864 4.254 3.88
    Total Liabilities 306.64 315.97 319.364 367.254 306.88
    Total Long Term Debt 0 0 0 0 0
    Total Equity 2214.1 2262.49 2275.97 2686.14 2721.3
    Common Stock 11.08 11.08 11.08 11.08 11.08
    Retained Earnings (Accumulated Deficit) 2239.53 2287.92 2301.4 2711.56 2746.73
    Treasury Stock - Common -36.508 -36.508 -36.508 -36.508 -36.508
    Total Liabilities & Shareholders’ Equity 2520.74 2578.46 2595.33 3053.39 3028.18
    Total Common Shares Outstanding 54.846 54.846 54.846 54.846 54.846
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Cash From Operating Activities 231.131 -94.787 262.449 215.021 107.792
    Cash Receipts 476.186 926.988 1008.57 754.16 1078.78
    Cash Payments -200.687 -962.091 -699.354 -493.508 -930.168
    Cash Taxes Paid -0.097 -0.139 -0.045 -0.039 -0.004
    Changes in Working Capital -44.271 -59.545 -46.723 -45.592 -40.812
    Cash From Financing Activities -233.271 91.768 -284.483 -205.213 -93.906
    Financing Cash Flow Items -1.726 -0.986 -0.883 -1.243 -1.086
    Total Cash Dividends Paid -212.242 -199.44 -188.36 -168.97 -182.82
    Issuance (Retirement) of Stock, Net -27.303 0.194 -8.24 0
    Issuance (Retirement) of Debt, Net 8 292 -87 -35 90
    Foreign Exchange Effects 1.253 -0.962 -1.857 -1.173 -2.544
    Net Change in Cash -0.887 -3.981 -23.891 8.635 11.342
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Cash From Operating Activities 203.086 231.131 291.426 258.426 221.081
    Cash Receipts 226.681 476.186 455.156 328.734 246.903
    Cash Payments -12.907 -200.687 -129.226 -46.042 -12.916
    Cash Taxes Paid -0.032 -0.097 -0.097 -0.078
    Changes in Working Capital -10.656 -44.271 -34.407 -24.188 -12.906
    Cash From Financing Activities -204.919 -233.271 -292.494 -260.317 -223.001
    Financing Cash Flow Items -1.108 -1.726 -0.949 -0.591 -0.248
    Total Cash Dividends Paid -156.311 -212.242 -212.242 -212.242 -212.242
    Issuance (Retirement) of Stock, Net 0 -27.303 -27.303 -18.484 -10.511
    Issuance (Retirement) of Debt, Net -47.5 8 -52 -29 0
    Foreign Exchange Effects 0.644 1.253 1.258 0.78 0.72
    Net Change in Cash -1.189 -0.887 0.19 -1.111 -1.2

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    BB Biotech Company profile

    About BB BIOTECH AG

    BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, BB BIOTECH AG revenues decreased from SF741.8M to -SF343.6M. Net loss totaled SF404.8M vs. income of SF691.2M. Revenues reflect Unrealized Gains/Losses on Securities decrease from SF460.9M to -SF652.2M, Dividend Income decrease from SF243K to SF0K, Other income decrease of 83% to SF4K. Net loss reflects Management fees increase of 27% to SF50.7M (expense).

    Equity composition

    3/2016, 5-for-1 stock split (Factor: 5).

    Industry: Biotechnology & Medical Research (NEC)

    Schwertstrasse 6
    SCHAFFHAUSEN
    SCHAFFHAUSEN 8200
    CH

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    Gold

    2,389.89 Price
    +0.350% 1D Chg, %
    Long position overnight fee -0.0190%
    Short position overnight fee 0.0108%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    XRP/USD

    0.50 Price
    -1.060% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    BTC/USD

    64,297.45 Price
    +1.240% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    US100

    17,205.50 Price
    -0.770% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading